Compass Therapeutics
NASDAQ: CMPX
Develops antibodies targeting tumor-immune synapse for comprehensive cancer treatment.
Develops antibodies targeting tumor-immune synapse for comprehensive cancer treatment.
F-Prime Team
Sector
Life SciencesCategory
TherapeuticsLocation
Cambridge, MAInitial Investment
2015Compass Therapeutics (NASDAQ: CMPX) is comprehensively drugging the tumor-immune synapse with human antibodies against over 50 cell surface and soluble targets.